Multiple myeloma: toxicity lower with subcutaneous bortezomib

  • Zhang HM, et al.
  • Cancer Manag Res
  • 10 Sep 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with newly diagnosed multiple myeloma (NDMM), subcutaneous (SC) administration of bortezomib delivered comparable response rates and survival outcomes vs intravenous (IV) administration, but with a notable reduction in toxicity.   

Why this matters

  • Limited evidence suggests that SC administration of bortezomib may lead to a reduction in adverse events (AEs) in this setting when compared with IV administration.

Study design

  • Study to compare the efficacy and safety of bortezomib with IV (n=100) or SC (n=105) administration in 205 patients with NDMM.
  • Median patient age, 61 (range, 27-82) years.
  • Funding: National Natural Science Foundation of China; Henan Outstanding Person Foundation.

Key results

  • After cycle 1:
    • 31.0% very good partial response or better (≥VGPR) with IV vs 14.3% with SC (P=.004).
  • No significant difference in overall response rate (ORR) by administration method for cycles 2-6 (P>.05).
  • Median PFS, 37 months with IV vs 45 months with SC (P=.774).
  • Median OS, 63 months with IV vs 59 months with SC (P=.667).
  • Generally lower incidence of grade ≥3 AEs with SC vs IV.
  • 35.2% incidence of overall peripheral neuropathy with SC vs 51.0% with IV (P=.023).

Limitations

  • Retrospective data in Chinese patients.